Prevalence and risk factors of urinary tract infection in kidney recipients: a meta-analysis study

Hosseinpour, Masoumeh; Pezeshgi, Aiyoub; Mahdiabadi, Morteza Zaboli; Sabzghabaei, Foroogh; Hajishah, Hamed; Mahdavynia, Soheila

doi:10.1186/s12882-023-03338-4

BMC Nephrology

Table 2 Characteristics of the articles reviewed in this study

From: Prevalence and risk factors of urinary tract infection in kidney recipients: a meta-analysis study

AUTHOR Ref	Year	No. of participants	Country	Mean age	Male/female (n)	% UTI	Deceased donor/ living donor	Antibiotic prophylaxis	Study design	Risk factors investigated	Mean follow-up (mo)
Bonkat G [42]	2012	78	Switzerland	56	51/27	27	50/28	Sulfanamid	Cohort	Age, female sex, previous history of UTI	24
Sorto R [43]	2010	176	Mexico	37	96/80	35	38/138	B lactam	Cohort	Age, female sex, deceased donor, duration of catheter, diabetes, use of ureteral stent, abnormal anatomy of urinary tract, antibiotic prophylaxis	48
Golebiewska J [69]	2011	89	Poland	48.1	52/37	55	88/1	B lactam	Cohort	Age, female gender, previous history of UTI, acute rejection, use of ureteral stent	12
Farr A [70]	2014	598	Austria	54	389/209	31	57/521	Sulfanamid	Cohort	Age, female gender	18
Papasotiriou M [24]	2011	122	Greece	44	75/47	60.7		Sulfanamid	Cohort	Female gender, diabetes, acute rejection	68
Vidal E [33]	2012	2172	Spain	52	1381/671	7.3		Sulfanamid	Cohort	Age, female sex, previous history of UTI, diabetes, acute rejection	18
Giullian JA [71]	2008	158	USA	47	109/49	16	67/76	Sulfanamid	Cohort	Female gender, deceased donor, Diabetes, abnormal anatomy of the urinary tract, antibiotic prophylaxis	36
Dantas S [39]	2006	163	Brazil	42.5	98/65	44.7	110/53	Sulfanamid	Cohort	Deceased donor, duration of catheter	24
Chuang P [6]	2005	500	USA	44	331/169	43	105/195	B lactam	Cohort	Age, female gender, deceased donor	42
Pellè G [72]	2007	177	France	46.5	117/60	75	153/24	B lactam	Cohort	Female gender, previous history of UTI, acute rejection,	22
Memikoglu KO [73]	2007	136	Turkey	32	88/48	41	33/103	B lactam	Cohort	Female gender, use of ureteral stents	38
ópez-Medrano F [74]	2014	163	Spain	44.8	107/56	9.8	140/244		Cohort	Female gender	26
Safdar N [44]	2005	385	USA	47	166/218	50	607/141		Cohort	Female gender, previous history of UTI, duration of catheter, diabetes, use of ureteral stent, abnormal anatomy of urinary tract, antibiotic prophylaxis	96
Wojciechowski D [11]	2013	236	USA	51.6	145/91	32.6	95/141	Sulfanamid	Cohort	Age, female gender, deceased donor, use of ureteral stent	12
Espinar MJ [61]	2015	98	Portugal	53.8	35/63				case control	Previous history of UTI, diabetes, antibiotic prophylaxis	9
Bodro M [75]	2015	867	Spain	60		20		Sulfanamid	Cohort	Age, female gender	90
Bodro M [45]	2015	867	Spain	60	520/347	21	662/205	Sulfanamid	Cohort	Female gender, deceased donor, diabetes, acute rejection	90
Ariza-Heredia EJ [67]	2014	301	USA	56.7	177/124	34	123/132	B lactam	Cohort	Female gender, use of ureteral stents, abnormal anatomy of the urinary tract	24
Naik AS [77]	2015	60,702	USA	52	36,725/23977	32	44,616/16086		Cohort	Age, female gender, deceased donor, diabetes	132
Liu S [78]	2016	103	China	35.4	79/24	17.4		B lactam	RCT	Age, female sex, use of ureteral stent	48
Hazratullah E [63]	2022	74	Pakistan		62/12	36.4		Sulfanamid	Cohort	Female gender, previous history of UTI, diabetes, acute rejection, abnormal anatomy of the urinary tract	3
Hazratullah E [63]	2022	74	Pakistan		62/12	36.4		Sulfanamid	Cohort
Mansury D [79]	2018	356	Iran		206/150	31.5	241/115		Cohort	Female gender, deceased donor,	48

Back to article page

ISSN: 1471-2369

Contact us

Submission enquiries: bmcnephrology@biomedcentral.com
General enquiries: ORSupport@springernature.com